Back to top

Analyst Blog

Sanofi’s (SNY - Analyst Report) subsidiary Genzyme recently announced that its oral candidate for relapsing forms of multiple sclerosis (RMS), Aubagio (teriflunomide) 14 mg, has gained approval from Argentina’s National Administration of Drugs, Food and Medical Technology (ANMAT). The ANMAT approved Aubagio as a once-daily treatment for patients with RMS.

The Argentinean approval came on the basis of data from a pivotal phase III study (TEMSO) in patients with RMS. In the trial, Aubagio demonstrated promising efficacy and safety profile.

We note that Argentina is the third country where Aubagio received approval. Aubagio received approval in the US (Sep 2012) and Australia (Nov 2012) as a once-daily treatment for patients with RMS. Aubagio is under review in many other countries.

In Mar 2013, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of Aubagio. However, CHMP did not recommend a new active substance (NAS) designation for Aubagio. Sanofi is planning to request a re-examination of CHMP’s decision in relation to the NAS designation.

Aubagio generated US sales of €7 million in the fourth quarter of 2012. We believe that Aubagio represents significant commercialization opportunity.

Sanofi has another RMS candidate, Lemtrada (alemtuzumab), in its pipeline. The FDA’s decision regarding the approval of Lemtrada is expected in the second half of 2013.

We note that apart from Aubagio, FDA approved oral multiple sclerosis therapies include Novartis’ (NVS - Analyst Report) Gilenya and Biogen Idec’s (BIIB - Analyst Report) Tecfidera (dimethyl fumarate, formerly BG-12).

Sanofi carries a Zacks Rank #4 (Sell) in the short run. Right now, Novartis and Allergan Inc. (AGN - Analyst Report) look more attractive in the pharma space with a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.35 +4.82%
CENTURY ALU… CENX 22.42 +3.99%
ERBA DIAGNO… ERB 2.90 +3.94%
MALLINCKROD… MNK 71.88 +3.41%
GTT COMMUNI… GTT 12.03 +3.26%